STING1 and COVID-19: This aligns with empirical research, demonstrating a significantly heightened risk of severe disease and mortality when SARS-CoV-2 infection is accompanied by conditions such as bacteremia, mycobacterial infection, influenza, and leptospirosis.[79–82] Given that Myristate can be dietary supplemented, it is suggested that Myristate supplementation mitigates the risk of severe COVID-19 during coinfections.[83] This also presents novel opportunities for the therapeutic targeting of STING inhibitors in the treatment of co-occurring infections alongside COVID-19.